anti-Parkin phospho (Ser101) antibody

anti-Parkin phospho (Ser101) antibody for Western blot and Human

Cell Biology and Cellular Response antibody; Metabolism antibody; Neuroscience antibody


Product Description Rabbit Polyclonal antibody recognizes Parkin phospho (Ser101)
Tested Reactivity Hu
Predict Reactivity Bov, NHuPrm
Tested Application WB
Host Rabbit
Clonality Polyclonal
Isotype IgG
Target Name Parkin
Antigen Species Human
Immunogen Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser101 conjugated to KLH
Conjugation Un-conjugated
Alternate Names AR-JP; EC 6.3.2.-; PRKN; Parkinson juvenile disease protein 2; E3 ubiquitin-protein ligase parkin; PDJ; Parkin; LPRS2; Parkinson disease protein 2

Application Instructions

Application Suggestion
Tested Application Dilution
Application Note Specific for the ~52k parkin protein phosphorylated at Ser101 . Immunolabeling of the parkin band is absent in parkin S101 mutants.
* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.


Form Liquid
Purification Affinity Purified
Buffer 10 mM HEPES (pH 7.5), 150 mM NaCl, 0.1 mg/ml BSA and 50% Glycerol
Stabilizer 0.1 mg/ml BSA, 50% Glycerol
Storage Instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.


Database Links

GeneID: 5071 Human PARK2

Swiss-port # O60260 Human E3 ubiquitin-protein ligase parkin

Gene Symbol PARK2
Gene Full Name parkin RBR E3 ubiquitin protein ligase
Background Parkin is an E3 ligase in the ubiquitin-proteasome system. Hereditary Parkinson’s disease is most commonly caused by mutations in the parkin gene and is characterized by the progressive loss of dopaminergic neurons and the presence of Lewy bodies in the substania nigra (Jenner et al.,1992). Recent evidence suggests that phosphorylation of parkin at Ser101 may have an important regulatory role on its E3 ubiquitin ligase activity (Yamamoto et al., 2005).
Research Area Cell Biology and Cellular Response antibody; Metabolism antibody; Neuroscience antibody
Calculated MW 52 kDa
PTM Auto-ubiquitinates in an E2-dependent manner leading to its own degradation (PubMed:19229105). Also polyubiquitinated by RNF41 for proteasomal degradation.
S-nitrosylated. The inhibition of PRKN ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PRKN substrates.
Phosphorylation at Ser-65 by PINK1 contributes to activate PRKN activity. It is however not sufficient and requires binding to phosphorylated ubiquitin as well.

Images (1) Click the Picture to Zoom In

  • ARG52389 anti-Parkin phospho (Ser101) antibody WB image

    Western blot: HEK293 cells transfected with Parkin WT (Phospho) and Parkin S101 mutant (non-phospho) showing the phospho-specific immunolabeling of the ~ 52 k parkin protein stained with ARG52389 anti-Parkin phospho (Ser101) antibody. The immunolabeling is absent in the parkin S101 mutant.